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NATURAL KIL LER LYMPHOCYTE MEMBRANE ANTIGENS INVOLVED IN 
ALLORECOGNITION TARGETING. Kevin E. Bishoff, Jeffrey R. Bender. 
Section of Cardiovascular Medicine, Department of Internal Medicine, 
and the Molecular Cardiobiology Program, Boyer Center for Molecular 
Medicine, Yale University, School of Medicine, New Haven, CT. 
It has been recently established that natural killer (NK) 
lymphocytes have alloantigen recognition capabilities, although the 
membrane receptor(s) involved is unknown. In the current study, I 
attempt to characterize such receptors, utilizing an immortal B cell 
line (RPMI8866) which drives the clonal expansion of antigen- 
specific NK cells. My hypothesis is that NK cells have a receptor 
structure that enables them to recognize and specifically lyse these 
targets. 
Murine monoclonal antibodies (mAbs) specific for NK cells were 
generated and screened by flow cytometry for NK cell specificity and 
effect on NK cell function. Utilizing RPMI8866-stimulated NK cells as 
effectors, 2 mAbs (1F7 and 1F8) were defined which partially inhibit 
lysis (54% and 36% inhibition, respectively, at a 33:1 effector to 
target ratio) of the stimulating RPMI8866 cell line but not the 
classical NK-sensitive target K562 at any effector to target ratio. 
These results support the hypothesis that NK cells have surface 
receptors involved in specific target recognition and describe two 
mAbs which appear to recognize such structures. 
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Natural killer (NK) cells are a bone marrow derived subset of 
lymphocytes found in blood and lymphoid tissues (1). NK cells 
comprise 1% to 25% of cells in the peripheral blood of humans (2). 
Because they appear morphologically as large cells with numerous 
cytoplasmic granules, NK cells are also called large granular 
lymphocytes (LGLs) in the literature. In a manner analogous to 
cytotoxic T lymphocytes (CTLs), NK cells kill their targets by granule 
exocytosis and secretion of a cell toxin. However, unlike CTLs, NK 
cells do not require prior contact with target antigens to develop 
cytolytic capacities or cytokine responsiveness (1). The name 
'natural killer' refers to this ability to lyse certain cells without prior 
sensitization or restriction by major histocompatibility complex 
(MHC) class I or II gene products (2-4). That is, they mediate 
cytolytic reactions that do not require expression of class I or class II 
MHC molecules on the target cells (3). 
Although there is a subset of T cells which can also lyse their 
targets in an MHC-unrestricted fashion, NK cells are distinct from this 
subset in that they lack the surface molecule CD3 and the T cell 
receptor (TCR) for antigen recognition. Unlike B and T cells, 
respectively, NK cells do not undergo Ig or TCR rearrangement, 
which, via the creation of a variety of surface receptors, enables 
them to specifically recognize antigens. Lymphocytes without slg or 
TCR perform "nonspecific" lethal action on various susceptible cell 
types but, in general, were previously considered unable to recognize 
antigen(s). 
From its discovery in 1974 until very recently, identification of 
the NK cell based solely on its morphologic characteristics, and on 
certain of its known functions, some which are shared with other cell 
types, such as monocytes, macrophages and activated T cells, posed a 
major limitation to NK cell analysis. Monoclonal antibodies (mAbs) to 
cell surface molecules can phenotype NK cells, differentiating them 
from other lymphoid cells with common cytotoxic activity or 
morphology. Surface antigens expressed on human NK cells include 
class I, CD2, CD7, CD8, CDlla, b, c/CD18 (LFA-1, Mac-1, pl50,95), 
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CD16 (the NK cell Fc receptor for IgG), CD56, and CD57 (5). Although 
none of these antigens is unique to NK cells, the combination of CD 16 
and CD56 on a cell lacking the T cell-associated CD3 molecule, is 
thought to be definitive of the NK cell. 
The clinical relevance of the NK cell is still a matter of debate 
as its function and purpose in normal immunity is not completely 
understood. Given the lag period between exposure to foreign 
materials and the development of specific immunity, NK cells were 
initially thought to be a part of a primary broader-range defense 
system that can act almost immediately until specific immunity 
develops (4). However, from in vitro experiments, it has been 
inferred that NK cells produce lymphokines including interleukin 2 
(IL-2) and interferon alpha, and serve in a regulatory capacity to the 
adaptive immune system and to hematopoiesis, in addition to 
confering 'natural' resistance against tumors, microbes, fungal, and 
parasitic agents (6,7). Moreover, it is not known whether all these 
functions can be mediated by the same cells or whether distinct 
functional subsets within the NK cell population have different 
activities (7). Since NK cells have been shown to secrete a variety of 
lymphokines, it is also not known which of these functions is 
mediated by direct cytotoxicity and which is mediated through 
lymphokine secretion (7). 
NK cells are able to kill virally infected cells and malignant 
transformed cells in vitro, however they have not been found in 
inflammatory infiltrates associated with viral infection or tumor (1). 
The great potential of clinical benefit from understanding NK cell 
function stems from the wide range of possible targets of NK cell 
killing, and perhaps that there exist functions beyond cytolysis, 
including target cell activation and amplification of immune 
responses. 
Early work with NK cells completed in animals revealed their 
significance in the immune surveillance against the establishment of 
primary tumors, as well as in controlling the spread of distant 
metastases (8). IL-2 in vivo and in vitro enhance NK cell cytolytic 
activity, enabling them to lyse tumor-cell targets that are resistant to 
unstimulated NK cells (8). Not only the range of tumor cell 
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recognition, but also the intensity of killing, was shown to highly 
increase after culture of NK cells in IL-2 containing media (9). In 
addition, NK cells can be induced to proliferate by high 
concentrations of IL-2 (1). The effectiveness of these lymphokine- 
activated killer (LAK) cells has been evaluated in a series of clinical 
trials in which patients received recombinant IL-2 alone or in 
conjunction with LAK cells generated in vitro. The metastatic 
tumors, most often metastatic renal-cell carcinoma or melanoma, 
regressed in some of the patients who were treated with LAK cells or 
IL-2 (8). 
A number of studies in animals have identified a potentially 
important role for NK cells in the immune response to certain viral 
infections (8). In these experiments, NK cells responded rapidly to a 
viral challenge and mounted both a proliferative and a cytolytic 
response 4-6 days before a T cell response could be mobilized. There 
is a little evidence of such a role in humans. Partial deficiencies of 
NK cells have been documented in a variety of clinical circumstances, 
including Chediak-Higashi syndrome, leukocyte-adhesion-molecule 
(CD11/CD18) deficiency, X-linked lymphoproliferative disorder (X- 
LPD), and the chronic fatigue syndrome. Unlike patients with X-LPD, 
in whom the NK cell defect is subsequent to EBV infection and might 
be induced by the virus, the NK cell-deficient patients had a history 
of repeated viral infection before EBV (6). 
In the few patients who have a selective absolute deficiency of 
NK cells, there is a prevalence of viral pathology. Biron et ai 
described one 17-year-old woman with a total deficiency of NK cells, 
but normal T and B cell function, who had life-threatening infections 
with three common herpesviruses: varicella, cytomegalovirus, and 
herpes simplex virus (8). Eventually specific T and B cell responses 
could be mobilized, but only after the one to two week time period 
required for recognition and amplification of these responses. From 
these data, it appears that NK cells, together with interferon and 
other natural resistance mechanisms, represent the first line of 
defense against infection by certain viruses. 
Their most impressive, and histologically supported, clinical 
function may be in the initiation of graft-versus-host disease (GVHD) 
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in the recipients of allotransplants. Postulated as central to the 
phenomenon of allograft rejection are the interactions between 
lymphocytes and microvascular EC, the initial allogenic barrier with 
which circulating host lymphocytes contact donor tissue in 
vascularized allografts (10). NK cells bind avidly to (10), induce the 
appearance of class II MHC antigens on (11), and promote striking 
morphologic alterations in microvascular EC (12) in vitro. Integral 
membrane protein lymphocyte function-associated antigen-1 (LFA- 
1) plays a major role in lymphocyte binding to microvascular EC (10), 
and consequently, induction of EC surface class II expression (11), 
which is viewed as a sign and a major stimulus of the rejection 
process (10). The surface density of LFA-1 on NK cells is 
approximately five times greater than that on CD4+ cells (13). 
In vivo data obtained mainly in the mouse suggests that NK 
cells are involved in the rejection of bone marrow transplants (14). 
NK cells are the effectors of the genetically restricted hybrid 
resistance to parental grafts (12). In humans Lopez et al. found an 
association between high pretransplantation NK cell activity in the 
recipient against HSV-1 infected target cells and incidence of GVHD 
after bone marrow transplantation (6). LGLs have been found in 
fine-needle aspirates from kidney transplant patients in the 
beginning and early stages of rejection, where their corresponding 
peripheral blood levels were much lower (15). However, the 
expression of CD 16 and CD56 on these LGLs was not reported. 
NK cells are found inside rat renal allografts during rejection. 
They appear, with strong cytotoxic activity, and disappear in situ, 
prior to the arrival of cytotoxic T lymphocytes (14). From these data, 
the authors hypothesized that NK cells may have a role in the 
maturation of the CTL, possibly acting as primary cells for CTL. 
Furthermore, the presence of NK cells in the renal allograft was 
simultaneous with their depletion from the spleen, suggesting that 
they are spleen-derived and not synthesized in situ. However, the 
surface markers on these cells were not characterized. 
Allogeneic lymphocyte cytotoxicity, the rapid destruction of i.v. 
injected allogeneic lymphocytes upon entering the host's lymphoid 
tissue, may be another nonadaptive immune response in which NK 
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cells play a role (16). Fossum and Rolstad reported that 
pretreatment with anti-NK cell antibodies (anti-asialo GMf and MRC 
OX-8) profoundly reduced the proportion of allogeneic cells 
phagocytozed by interdigitating cells (IDC). Additionally, the rate of 
killing of allogeneic lymphocytes differed substantially between 
cervical and axillary lymph nodes and this difference correlated with 
the densities of anti-asialo GMi+ cells in these nodes. In vitro 
studies with cell suspensions rich in IDC from peripheral lymph, but 
poor in NK activity, could not demonstrate allogeneic lymphocyte 
cytotoxicity (16). 
There is more than one mechanism by which NK cells 
recognize and kill their target. First, and most clearly understood, NK 
cell killing can be directed by opsonization of target cells with 
antibody. These IgG molecules are bound to CD 16, the FcR receptor 
for IgG, on the NK cell surface, triggering granule exocytosis and toxin 
secretion. NK cells are the principal mediator of this form of 
cytolysis, known as antibody-dependent cell-mediated cytotoxicity 
(ADCC) (1). The interaction with the FcR of NK cells may also evoke 
pleiotropic effects under permissive conditions, and is not restricted 
solely to the function of ADCC (17). NK cells can also lyse susceptible 
targets spontaneously by a second mechanism, which, although 
poorly understood, has generally been thought to occur without 
specificity and without MHC. Anti-IgG or anti-CD 16 FcR antibodies 
which inhibit ADCC do not prevent NK killing (6), indicating that in 
this type of killing, target recognition is not mediated via the Fc 
receptor that functions in ADCC killing (18). 
With the exception of the CD 16 FcR used in ADCC, there is no 
definitive information yet on any type of receptor used by NK cells 
for target cell recognition and killing (6). Despite the fact that NK 
cells have a limited target cell range, no specific NK-associated 
surface receptor or target ligand has yet been defined (19). 
Although a molecular structure recognized by NK cells has not been 
defined, there is evidence that NK cells are capable of killing with 
specificity in a non-ADCC, non-MHC restricted manner. 
The existence of NK specificity has been most simply 
demonstrated by the phenomenon of "cold target inhibition". In this 
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experimental situation one NK target cell type (unlabeled) can inhibit 
lysis of a different NK target type (labeled) by competing for effector 
cells (1), Cells that are not NK targets do not compete. Ciccone et at 
first reported specific lysis of allogeneic cells by CD3‘, CD2+, CD56+ 
lymphocytes after their activation in a mixed lymphocyte culture in 
the presence of exogenous IL-2 (20). After a ten day coculture, these 
cells displayed cytolytic activity against PHA-induced blast cells 
bearing the stimulating alloantigens but not against autologous or 
unrelated allogeneic blast cells (20). Coculture with an autologous 
stimulator, or without IL-2, did not result in cytolytic activity 
directed at autologous or allogeneic cells, although cytolytic activity 
against K562 erythroleukemia cells (a classical NK target) was 
preserved in these controls. From these MLC-stimulated CD3" cells, 
clones were derived that lysed allogeneic lymphoid cells with 
apparent specificity, although the expression of CD 16 and CD56 on 
these clones was not reported (19). 
CD3", TCR-, CD 16+ and/or CD56+ NK lines and clones with 
apparent antigen specificity have been described (19). In addition to 
displaying potent cytolytic activity against K562 cells, these clones 
lysed their specific stimulator lymphoblastoid cell line (LCL) to a 
significantly to a greater extent than irrelevant LCL. This selective 
killing was inhibited by the addition of cold simulator LCL or K562 
cells, or anti-LFA-1 mAbs, but not by irrelevant LCL or mAbs to CD3, 
class I or II MHC antigens (19). 
The presence of a novel "antigen receptor" that may recognize a 
set of polymorphic endothelial cell antigens distinct from human 
leukocyte antigens was suggested by a study by Bender et al. They 
used cytotoxicity assays to demonstrate the ability of NK cells to lyse 
preferentially the line of microvascular endothelial cells to which 
they were previously bound for only 90-min (21). CD3", CD16+ 
lymphocytes preferentially killed endothelial cells (ECs) with which 
they were cocultured over endothelial cells of unrelated donors (21). 
Antibodies blocking CD3, CD4, CD8, class I and II did not block killing, 
whereas anti-LFA-1 antibody consistently inhibited cytotoxicity, 
likely because of its role in leukocyte binding to ECs (21). Their 
results suggest that cytotoxic NK lines bind to their stimulating ECs 

7 
via both nonspecific and specific ligand interactions, and further 
suggest that the basis for their specific cytotoxicity may lie, at least 
in part, with specific binding (21). 
As the membrane target structures have not been identified, it 
is not known whether different NK cells react with the same or with 
different target antigens (7). In fact, many studies have indicated 
that NK cells are not a homogeneous population in regard to 
expression of surface markers and cytotoxicity (22) but rather that 
subsets of NK cells recognize one or a limited number of target cells. 
Allavena and Ortaldo studied the heterogeneity among many clones 
of human NK cells with regard to phenotype and their patterns of 
cytotoxic reactivity towards a variety of tumor target cells (22). To 
determine whether the tumor specificity and surface antigenic 
profiles of NK cells are clonally distributed or whether individual 
clones of NK cells display the heterogeneity associated with the 
entire NK cell population, they tested the cytotoxicity of 196 clones of 
cultured LGL from three donors against a panel of tumor target cell 
lines, and found that the receptors recognized on NK-susceptible 
targets are clonally distributed among the LGL population. 
Interestingly, they also found that although most clones 
demonstrated both NK and ADCC killing, some other clones, which 
had NK activity, did not have ADCC, or vice versa. However, the cell 
surface phenotype of many of the LGL-derived clones included T cell 
markers, and the heterogeneity may represent different cell 
populations and not subsets of a single NK cell population. 
NK cells isolated from individuals exhibit different 
allospecificities expressed by normal allogeneic target cells (23). 
Allavena and Ortaldo used their data from clones derived from 
purified preparations of LGL to support the hypothesis that the 
heterogeneity of the entire NK population is attributable to a mixture 
of clones that vary substantially in their target specificities and 
phenotypes (22). Regardless, while antigen-specific receptors have 
not been defined, and the molecular basis for such activity unknown, 
these studies indicate that NK cells do kill allogeneic cells selectively. 
Furthermore, this ability appears to be clonally distributed. In 
addition, the experimental data hint at the possibility of an NK cell 
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repertoire for the recognition of allogeneic cells, albeit a limited one 
in comparison to the T or B cell repertoire. 
Now that it has been established that at least a subset of NK 
cells recognize allogeneic cells, the question posed is how is this 
specificity is achieved? Some research indicates that specific NK 
killing is MHC restricted. An inverse relationship between the 
expression of class I MHC antigens on target cells and sensitivity to 
NK reactions has been reported by several groups (3). Dawson et al. 
described studies in which infection of NK sensitive cells by strains of 
adenovirus known to decrease MHC class I molecule expression 
greatly enhances cytotoxicity (3). In general, target cell MHC class I 
antigen expression correlates with resistance to NK cell-mediated 
lysis (24). Thus, the potential role of MHC gene products as signal 
structures altering recognition by NK cells remains controversial (3). 
Two models originally proposed to explain recognition of MHC 
class I deficient cells in murine hybrid resistance are applicable to 
the human alloreactive NK cell clones discussed above (25). They are 
called 'effector inhibition' and “target interference? In the effector 
inhibition' model, NK cell-surface molecules engage MHC class I 
antigens which consequently deliver inhibitory signals, requiring NK 
cell receptors that distinguish between different MHC class I alleles. 
In target interference, the NK cell receptors for specific antigens 
would not bind to target structures as they are masked by 
autologous MHC class I alleles. 'Target interference’ requires that NK 
cell receptors recognize different non-MHC target structures, and that 
MHC class I alleles can distinguish and interact with different target 
structures. 
Supporting the effector inhibition' model is the hybrid 
resistance phenomenon, the MHC-linked, NK cell mediated rejection 
of homozygous parental bone marrow grafts by heterozygous Fj 
irradiated mice. Studying scid/scid mice challenged with H-2 
homozygous bone marrow cells that are either Hh-1+ or Hh-1", 
Murphy et al. presented evidence that these noncodommantly 
inherited histocompatibility determinants may be specifically 
recognized by NK cells, leading to graft rejection (3). 
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These models are not mutually exclusive and the 'masked' 
nonself determinant in the target interference model might be a 
polymorphic, MHC-encoded Hh antigen (25). In both models, a 
somatic, MHC-controlled determination of the NK cell receptor 
repertoire would be necessary for self-tolerance. This is supported 
by studies on human alloreactive NK cell clones, and by studies of 
hybrid resistance, H-2 transgenic and beta2-m knockout mice (25). 
The studies on human alloreactive NK clones, as well as mouse 
hybrid resistance and transgenic studies, stress the non¬ 
responsiveness to self and the reactivity to qualitatively MHC- 
mismatched targets (25). Studies of transgenic mice provided 
evidence that MHC class I genes regulate the NK repertoire of 
transplant recipients as well as the NK susceptibility of grafted cells 
(25). Bone marrow cells from gene "knockout" mice indicate that loss 
of MHC class I expression leads to NK sensitivity (25). 
Karlhofer et al. reported that NK cells with a surface molecule 
(LY-49) that specifically interacts with the peptide-binding domains 
of the MHC class I alloantigen do not lyse cells with the MHC domain, 
despite efficient spontaneous lysis by Ly-49‘ effector cells (24). In 
order to characterize NK cell-mediated specificity, Ciccone et al. 
studied the target cells to determine that susceptibility to lysis is 
inherited in an autosomal recessive fashion (26). They found that 
lysis of normal allogeneic cells by NK cells can be clearly 
distinguished from conventional non-MHC restricted lysis of tumor 
cells (26). While cloned NK cells specifically lysed appropriate 
normal allogeneic cells, the lysis of tumor target cells was clearly 
unrelated to this phenomenon (26). 
Even so, most research supports that hypothesis that specific 
NK killing is non-MHC restricted. Regarding antigens seen by NK 
cells, it is agreed that the expression of either class I or class II MHC 
gene products on target cells is not required for the development of 
cytotoxicity. Suzuki et al. showed that antibodies to HLA class I, or 
HLA-DR had no effect on the lysis of target by either NK killing (of 
K562) or specific NK killing (of stimulator lymphoblastoid cell line) 
(19). 

What then, could be the nature of the structures expressed on 
non-MHC restricted NK cells conferring upon those cells the capacity 
to recognize their targets? Little is known about the molecules 
involved in non-MHC-restricted killing. Several theories have been 
postulated. First, non-MHC-restricted killing may be mediated by 
multiple cell interaction/adhesion molecules present on the cell 
surface interacting with their natural ligands on the target cell. 
Selectivity of NK cells might be determined by the relative 
expression of several cell surface molecules and receptors, with no 
single molecule playing a unique and essential role (6). Such 
molecules include CD11/CD18, CD2, and CD45 present on NK cells. 
Sufficient engagement of one or more of these molecules could result 
in NK cell activation and target cell death (27). 
The surface molecules of the CD! 1/CD 18 family appear to play 
important functional roles in NK cell killing. Patients with selective 
deficiency of either are deficient in NK cell activity, which is 
probably a consequence of inability to bind target (6). CD56 may 
play an accessory role as a mediator of nonspecific adhesion between 
allospecific NK effectors and their targets. However, given the 
existence of multiple isoforms, the variable expression of these 
isoforms on allospecific NK lines, and the failure of any of anti-CD56 
mAbs to affect the lysis by NK cells of "nonspecific" targets, such as 
K562, the likelihood that CD56 plays an accessory role as a mediator 
of nonspecific adhesion is poor (2). 
Laminin, which increases on the NK cell surface upon 
stimulation with IL-2, may act in prolonging lysis (6). Schwarz and 
Hiserodt demontrated that IL-2 activated NK cells which generate 
broadly reactive non-MHC restricted cytotoxicity express laminin¬ 
like molecules on their surface while cells not expressing these 
activities do not appear to express such structures (28). 
Furthermore, anti-laminin antibodies block cytotoxicity at a 
postbinding stage, without inhibiting NK-target cell interaction (6). 
Another theory is that non-MHC restricted specificity may be 
conferred by NK cell-specific 'Teceptor(s)" that interact with specific 
moieties expressed on NK-sensitive target cells. Non-MHC-restricted 
killing of K562 leukemia cells by CTLs could be inhibited by 

antibodies to CD3/TCR, suggesting that these cells may recognize 
target via the CD3/TCR receptor (5). Although an NK target 
recognition structure has not been identified, several molecules have 
been described that are NK cell-specific and appear to modulate NK 
cell-mediated killing, including two on human NK cells (27). 
Moretta et al. identified functional surface molecules which are 
expressed variably within NK cell clones and presence of one 
combination of these markers correlated with NK cell ability to 
mediate specific lysis of normal allogeneic cells (29). This study 
implicated the involvement of one molecule, EB6, in specific NK cell 
recognition. However, other NK clones possessing the EB6 molecule 
did not lyse the specific target, further complicating the 
interpretation of the molecule's significance. 
Moretta et al. also described GL183, a cell surface molecule 
present on a phenotypically stable subset of NK cells whose cytolytic 
behavior is modulated by anti-GL183 mAb (9). However, GL183 
probably acts more as an regulator of function and is less likely to be 
involved in alloantigen-specific recognition as it is invariant in 
structure (2) and is not associated exclusively with NK activity (18). 
CD2 and CD 16, which have been shown to mediate signal 
transduction and activation of cytoxic mechanisms, are unlikely 
candidates for the same reasons (2) and that mAbs directed against 
them fail to inhibit recognition and lysis of NK-susceptible target 
cells (30). 
Monoclonal antibodies specific for CD45 have been reported to 
inhibit NK cell lysis of selected tumor cells, suggesting a possible role 
in conferring NK specificity, however CD45 is not NK cell-specific, as 
it is expressed on the majority of hematopoietic cells (30). 
CD56, of which at least four distinct isoforms have been found, 
exist variably on allospecific NK lines (2). Two mAbs, which by 
immunoprecipitation analysis revealed they recognized distinct 
molecular isoforms of CD56, were generated that bound selectively to 
the majority of CD3", CD16+, CD56+ lymphocytes. They inhibited the 
lysis of specific allogeneic target cells by a panel of alloreaetive NK 
lines, without affecting the ability of these cells to kill the classical 
NK target K562 (2). The role of CD56 in NK killing is incompletely 

understood, however, the finding of multiple CD56 isoforms on NK 
cells is consistent with the hypothesis that these isoforms constitute 
an allorecognition apparatus with limited heterogeneity. In studies 
by Nitta et aL, however, the contribution of CD56 to NK cell 
cytotoxicity and binding could be demonstrated only when the target 
cells also express CD56 (31). This would limit the target cell 
population of CD56 mediated toxicity to neural and muscle cells, 
which contain the N-CAM isoform, and other CD56 containing tissues. 
In the current study, I attempted to further characterize 
membrane antigens on the surface of NK cells which are involved in 
alloantigen target recognition. Previously this lab created NK cell 
lines and clones against RPMI8866, an immortalized B cell line, which 
preferentially lysed the stimulating B cell line and were minimally 
cytotoxic for a third party of autologous B cell targets (Bender, 
unpublished data). A monoclonal antibody called C8, also created in 
this lab, was specific for a surface molecule on RPMI8866 and, when 
incubated in cytotoxicity assays, blocked killing of the RPMI8866 
target cell but not of K562. In fact, there were CDS', CD3", CD16+, 
CD56+ RPMI8866-stimulated NK clones whose lysis of RPMI8866 
cells was 100% inhibited by monoclonal C8. From these data, it was 
concluded that RPMI8866 cells are specifically recognizable NK 
targets, and that the molecule recognized by C8 is a target ligand on 
the B cell which binds to a putative NK receptor. 
My project was directed at proving the hypothesis that the NK 
cells generated by stimulation with these B cells do have a receptor 
structure that enables them to recognize and specifically lyse these 
targets. Murine monoclonal antibodies specific for CD3", CDS', CDS' 
NK cells were generated and screened for specificity to the activated 
NK cell and effect on NK cell behavior in cytotoxicity assays. 
Antibody binding was measured on fresh NK cells versus NK cells 
activated by co-culture with RPMI8866. Cytotoxicity assays 
compared the effect of antibody on NK killing of the specific target, 
RPMI8866 B cells, with general cytotoxicity of K562. The results 
support the hypothesis that NK cells have surface molecules which do 




Isolation of CDS', CDS', CD8~, CD16+, CD56+ Lymphocytes. Peripheral 
blood mononuclear cells were isolated by Ficoll-Hypaque (Sigma, St. 
Louis, MO) gradient centrifugation and were monocyte and B cell 
depleted by plastic adherence followed by passage over nylon wool 
columns. To obtain CD3", CD5', CD8" cells, cells devoid of monocytes 
and B cells were incubated with anti-CD3 (7D6) mAb for 20 min. at 
4°C, washed twice, and applied to plastic petri dishes (Becton- 
Dickenson #1005) (which were precoated for at least twenty min. 
with 10 pg/ml goat anti-mouse IgG in Tris-HCl, pH 9.5, and washed 
with PBS) for 70 min. at 4<>C. (panning). Nonadherent cells were 
retrieved by gently washing the plates with cold PBS 1% FBS. They 
were then incubated with anti-CD5 (SI.6) mAb and panned on anti¬ 
mouse IgG to remove any residual CD5+ cells. Nonadherent cells 
were retrieved and incubated with anti-CD8 (3B5) mAb and panned 
on anti-mouse IgG to remove any residual CD8+ cells. The resultant 
lymphocyte population contained >90% CD56+ and <1% CD3+ cells by 
flow cytofluorometric analysis. 
Production of 1F7 and 1F8 mAbs. A 6-wk-old female BALB/c mouse 
was immunized with CD3-, CD5-, CD8-, CD16+, CD56+ NK cells. 
Immunizations were performed using Ribi adjuvant (Ribi 
Immunochem Research, Inc., Hamilton, MT) according to the 
manufacturer's protocol. The immunization schedule consisted of 3 
intraperitoneal injections of 10^ of the relevant cells in 0.5 ml. PBS. 
After the third immunization, the mouse was sacrificed humanely by 
cervical dislocation and splenectomized. The sensitized splenocytes 
were fused with SP2/0 murine myeloma cells (non-Ig producer), 
thus creating hybrid cells which produce antibodies directed against 
the immunizing NK cells. The hybridomas were placed in a limiting 
dilution, and 1 cell/well was placed in 96-well round-bottom plates 
(Becton-Dickinson, Lincoln Park, NJ). 
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Culture medium. Standard culture medium consisted of RPMI 1640 
(Biofluids, Inc., Rockville, MD or Gibco, Grand Island, NY) 
supplemented with 10% heat-inactivated fetal bovine serum 
(Biofluids), 1% (2mM) L-glutamine, and 1% streptomycin (100 pg/ 
ml)/penicillin (100 U/ml). Medium for NK cell cocultures included 
0,1% 2-Methionine (2-ME). Hybridomas were in HAT medium 
(standard plus 1% hypoxanthine-thymidine, 0.1% aminopterin) for 
first 2 weeks before being switched to HT (without aminopterin) and 
then standard. Hybridomas were grown in standard culture medium 
and split every 2 to 3 days. 
RPMI8866 Coculture. Peripheral blood lymphocytes were isolated on 
Ficoll-Hypaque gradients, and spun once at each 2000, 900, and 700 
rpms for 5, 10, and 15 min., respectively. The fast spin removed 
residual Ficoll, and the two slow spins removed platelets. Cells were 
brought up to a volume of 10^ cells/ml in standard medium plus 2- 
ME. 1 ml was placed in wells of 24-well flat-bottomed multi-well 
plates (Becton-Dickinson, Lincoln Park, NJ). RPMI8866 stimulator 
cells at 4 x 10^ cells/ml were Cs-irradiated at 6000 rads., and 0.5 ml 
was placed into each well. Cocultures were refed on days 7 and 10, 
and harvested on day 14, with about 70% CD3', CD16+, CD56+ cells by 
flow cytofluorometric analysis. Thereafter, the cocultures could be 
prolonged either in their wells or in bulk by refeeding with 
irradiated RPMI8866 stimulator cells at a ratio of 2 x 10^ feeders: 
106 NK cells on a weekly basis. 
Screening of Hybridoma Supernatants. 166 hybridoma supernatants 
were screened on the basis of their ability to bind to activated CD3", 
CD5", CD8‘, CD16+, CD56+ lymphocytes by flow cytofluormetric 
analysis. 123 hybridoma supernatants were also screened for 
staining on RPMI8866 B cells and 99 were tested for antibody 
binding to CD3+ T lymphocytes. 19 predominantly NK cell specific 
antibody secreting hybridomas were then evaluated in cytotoxicity 
assays with RPMI8866 targets. Of these, 2 antibodies were also 
tested in cytotoxicity assays with K562 as targets. When screening 
the hybridomas for antibody recognizing NK cells, the negative 

control antibodies used were HPCG14 (murine irrelevant IgGl) and 
OKT3 (anti-CD3), and the positive control antibodies were W6/32 
(anti-HLA class I) and 3G8 (anti-CD 16). When screening the 
hybridomas for antibody recognizing B cells, the negative control 
antibody used was HPCG14 and the positive control was C8 (anti- 
RPMI8866 cells). When screening the hybridomas for antibody 
recognizing T cells, the negative control antibody used was 3G8 and 
the positive control antibodies were OKT3 and 7D6 (anti-CD3). 
One and Two-color Flow Cytofluorometric Analysis. For surface 
marker analysis, 2 x 10^ cells were stained with the saturating 
amounts of appropriate mAb, and if unconjugated, washed and 
stained with fluoresceinated goat anti-mouse IgG+IgA+IgM(H+L) 
Double Staining Grade (Zymed). Each incubation was for 25 min. on 
ice to prevent cell-surface modulation of Ag. All samples were 
placed in 0.35 ml of staining buffer (PBS 1% BSA 0.1% sodium azide). 
Events were collected on a flow cytometer (FACSort, Becton- 
Dickinson, Mountain View, CA), gated to exclude nonviable cells, and 
analyzed with FACScan Research Software (LYSYS II, Becton- 
Dickinson). Results are expressed as arbitrary normalized 
fluorescence histograms, i.e., number of cells vs. fluorescence 
intensity. 
For two color staining, cells were stained with a FITC- 
conjugated antibody for 10 min. and then a PE-conjugated antibody 
for 15 additional min. before the cells were washed and placed in 
staining buffer. Controls for phenotyping the cells included cells 
stained with an irrelevant antibody bound to FITC and to PE. 
The mAbs used in these and other studies were anti-Leu-4- 
FITC (anti-CD3, AMAC, Inc.), anti-Leu 11-FITC (anti-CD 16, AMAC, 
Inc.), anti-CD56-PE (AMAC, Inc.), Irrel-FITC (Sigma), Irrel~PE 
(Sigma), HPCG14 (murine irrelevant IgGl), OKT3 and 7D6 (anti-CD3), 
SI.6 (anti-CD5), 3B5 (anti-CD8), W6/32 (anti-class I), 3G8 (anti- 
CD16), TS1.22 (anti-CDlla, anti-alpha subunit of LFA-1), C8 (anti- 
RPMI8866), anti-CD56. 
In order to determine whether mAbs 1F7 or 1F8 block binding 
of anti-CD56 antibody, CD3", CD16+, CD56+ lymphocytes were treated 

with 1F7 or 1F8 or anti-CD56 or 3G8 mAbs at 4°C for 30 min., 
washed and then stained with irrelevant PE second step to assess 
background blocking which was zero. The two test mAbs and anti- 
CD56 were incubated on separate NK cells, washed and stained with 
anti-CD56-conjugated PE second step and analyzed as above. 
(FITC=fluorescein isothiocyanate conjugated, PE=phycoerythrin- 
conjugated) 
Supernatant Concentration. Selected supernatants were concentrated 
to 25x with Centriprep-30 Concentrators (Amicon, Inc., Beverly, MA). 
After prerinsing concentrator with deionized water, supernatant was 
placed in concentrator and centrifuged at 2800 rpm for 15 min. 
Filtered supernatant was removed and the concentrator was re-spun 
twice at 2800 rpm for 5 min. each. Retentate was removed with 
syringe and syringe-filtered into aliquots for storage. 
Isotyping and Enzyme-Linked Immunosorbent Assay. Plastic ELISA 
plates were precoated with 1 pg/ml each of goat anti-mouse IgG and 
IgM in a coating buffer and incubated overnight at 4°C. Plates were 
washed twice with PBS 1% BSA 0.1% sodium azide and incubated 
overnight with PBS 3% BSA 0.1% sodium azide filling the wells. 
Plates were washed three times with .05%Tween-20. Test 
supernatants were added and incubated at 4°C 2 hours-overnight. 
Plates were washed three times with .05%Tween-20„ Goat anti¬ 
mouse conjugated alkaline phosphatase second step was added and 
the plate incubated at least 2 hours at room temp. Plates were 
washed three times with .05%Tween-20 and twice with PBS 1% BSA 
0.1% sodium azide. Disodium p-nitrophenyl phosphate (Sigma) 
substrate solution was added. Plates were read at 15 min. intervals 
by an ELISA-plate reader (Dynatech). 
Isotyping of selected antibodies was done using an ELISA- 
based isotyping kit (Southern Biotechnology Assoc., Birmingham, AL). 
Cytotoxicity assay. The most commonly used test of NK cell activity 
in vitro (assay for NK cell cytotoxicity) is the 51(> (sodium 
chromate)-release cytotoxicity assay, in which NK cell-containing cell 

preparations are mixed with a constant number of 51 Cr-labeled 
K562 or other target cells at one or more effector-to-target cell 
ratios, and cell lysis is evaluated, after 3-4 hours of incubation at 
37°C, by measuring the amount of ^Iq- released in the supernatant 
fluid (32). 
Cytotoxicity of NK cells against RPMI8866 cells and K562 cells 
was measured in a 4 h 51cr-release microcytoxicity assay using 96- 
well U-bottomed microplates (Becton Dickinson, Lincoln Park, NJ). 
The target cells were labeled with 75 pCi of Na2*^Cr04 per 1.5 x 10^ 
cells, washed, and seeded into 96-well culture dishes at 5 x 10^ 
cells/well in suspension. Test and irrelevant isotype-matched 
control antibodies at the same approximate concentrations were 
placed in appropriate wells in order to explore the role of cell surface 
molecules in cytotoxicity. Suspensions of effector cells were added to 
quadruplicate wells to give various E/T ratios, ranging from 100:1 to 
0.5:1, in a final volume of 200 jul. After an incubation at 37°C for 4 h, 
150 pi of supernatant was removed from each well and counted in a 
gamma counter to determine experimental release (ER). Spontaneous 
release (SR) was obtained from wells receiving target cells and 
medium only, and maximum release (MR) was obtained from wells 
receiving 1% Triton X-100. The percent cytotoxicity was calculated 
by the following formula: 
cytotoxicity = (ER)-(SR) x 100 
(MR)-(SR) 
SR was 20% of max when RPMI8866 cells were used as a target. SR 
was 7.5% of max when K562 cells were used as a target. 
Experimental replicates consistently varied by <10%. 
All work was performed by the author. Dr. Bender taught all 
experimental protocols and use of equipment, as well as assisting in 
early cytotoxicity assays and the running of FACSort samples in large 
experiments. Jean Wilson and Leslie Tacket instructed me on tissue 
culture technique and preparation of reagents. 

RESULTS 
Activation and proliferation of NK cells. Cell populations enriched in 
activated CD16+, CD56+ lymphocytes were obtained by coculture of 
PBLs with RPMI8866 cells for 2 wk. As shown in Figure 1A for a 
representative coculture, the resulting lymphocyte population was 
70% NK cells and 30% T cells by flow cytometry. Purification of CD3", 
CD8"’ CD16+, CD56+ NK cells was achieved by panning for removal of 
CD3+ T cells as described in Methods. Figure IB shows a phenotype 
representative of the nonadherent cells from a panning after 
incubation with mAb 7D6 (anti-CD3), >99% CD16+, CD56+ NK and 
<0.5% CD3+ T cells. Cells purified in this way were used in 
experiments requiring pure NK cell populations. 
A 
Figure 1. Two-color flow cytometric analysis of stimulated 
lymphocyte phenotype (A) after coculture of PBLs with RPMI8866 
cells; (B) of nonadherent coculture cells following panning with anti- 
CD3 mAb. FL1, recorded in log scale on the x-axis, indicates the 
intensity of FITC staining. FL2, recorded in log scale on the y-axis, 
indicates the intensity of PE staining. 

Evaluation of NK Cytotoxicity. To determine whether these CD3“, 
CD16+, CD56+ NK cells had cytolytic activity, they were tested as 
effectors in 4 h ^lcr-release assays against the original stimulator 
lymphoblastoid cell line, RPMI8866 as well as NK sensitive K562 
cells. As shown in Figure 2, these cells exhibited potent lysis of both 
RPMI8866 and K562 cells which titers with the E : T ratio. 
Effector: Target Ratio 
Figure 2. Cytotoxic activity of RPMI8866-stimulated CD3", CD16+, 
CD56+ NK cells was tested against the original stimulator RPMI8866 
cells and K562 cells. 
Expression of molecules on activated NK cells generated from 
peripheral blood. Among the 166 hybridoma supernatants tested 
against activated CD3", CD8", CD16+, CD56+ lymphocytes and analyzed 
by flow cytometry, 54 had antibody that bound to the NK cells. Of 
those antibodies, 37 also bound to molecules on the surface of B cells, 
and 19 also bound to molecules on the surface of activated CD3+ T 
cells. Of the 54 NK-positive antibody secreting hybridomas, 1 
produced antibody specific for NK cells with no staining of B or T 
cells (Figure 3), 3 which were negative on B cells but were slightly 
positive on T cells (Figure 4), 2 which were negative on B cells but 
very positive on T cells (Figure 5), 1 which was slightly positive on B 
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cells but negative on T cells (Figure 6), 3 which were slightly positive 
on both B and T cells (Figure 7), and 2 which were slightly positive 
on B and very positive on T cells (Figure 8). The rest were moderate 
to very positive on B cells, T cells, or both (data not shown). 
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Figure 3. Staining of mAb 3B8 on NK, B, and T cells. mAb 3B8 
recognizes a surface molecule unique to NK cells. 
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Figure 4. Staining of mAb 2G7 on NK, B, and T cells. This staining is 
representative of the three mAbs which recognize molecules which 
are present on NK cells and slightly on T cells, but absent on B cells. 
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Figure 5. Staining of mAb 4B9 on NK, B, and T cells, which is 
representative of the two mAbs which recognize molecules on NK 
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Figure 6. Staining of mAb 3F6 on NK, B, and T cells. The molecule 
recognized by mAb 3F6 is present on NK cells and a subset of B cells. 
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Figure 7. Staining of mAb 3E6 on NK, B, and T cells, which is 
representative of the mAbs which recognize a surface molecule on all 
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Figure 8. Staining of mAb 3D5 on NK, B, and T cells, which is 
representative of the two mAbs which recognize a surface molecule 
expressed highly on NK cells, moderately on T cells, and in low 
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Figure 9. Staining of mAbs A) 1F7 and B) 1F8, which, from data 
obtained by following experiments, were found to be of interest. 
Initially, it was concluded that mAb 1F7 recognized a surface 
molecule on NK, B, and T cells. However, it was later determined that 
mAb 1F7 was of IgM isotype (data to follow). This makes its staining 
pattern somewhat difficult to interpret, because an irrelevent 
antibody of IgM isotype was not used in the early screening 
experiments. Thus, the small amount of reactivity with B and T cells 
may be a consequence of nonspecific binding. This requires further 
evaluation. Monoclonal 1F8 recognizes a surface molecule which is 
on NK cells and less on T cells, but not on B cells. 
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Figure 10A, B, and C shows the controls for the staining of 
CD3-, CD8", CD16+, CD56+ NK cells, RPMI8866 B cells, and CD3+, CD16' 
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Figure 10. One-color flow cytometric analysis of cell surface 
antigens on three cell types. Positive and negative controls used for 
staining (A) NK cells; (B) B cells; and (C) T cells. In experiments 
using CD3", CD8~, CD16+, CD56+ NK cells obtained as described in 
Methods, HPCG14, OKT3, and 3B5 were negative controls, while 3G8 
was the positive control. For RPMI8866 B cells, HPCG14 was 
negative, while C8 was positive. For CD3+, CD 16' T cells, 3G8 was 
negative, while OKT3 and 7D6 were positive. 

Isotyping of mAbs. Using an ELISA-based isotyping kit, mAh 1F7 
and 1F9 were determined to be IgM, while mAbs 1E8, 1F8, 2G7, 3B8, 
and 3E6 were found to be of IgGl isotype. The negative controls 
were standard medium and PBS 1% BSA 0.1% sodium azide. Positive 
control for IgGl was mAb 3G8 (anti-CD 16). Positive control for IgG2a 
was OKT3 (anti-CD3). Positive control for IgM isotype was mAb 
1H12, an endothelial cell specific antibody. The results are shown in 
Table 1. 


























In experiments requiring isotype-specific controls for mAbs 1F7 and 
1F8, mAbs 1H12 and 2G7 were used, respectively. 
Functional role of molecules bound by mAb in cytotoxicity by 
activated NK cells. The functional involvement of molecules bound 
by these mAbs was tested. CD3', CD16+, CD56+ NK cells were tested 
for cytotoxic activity against RPMI8866 cells in the presence and 
absence of mAbs. The results of these experiments are shown in 
Figure 11, A and B. Although cytotoxic activity was high against the 
target tested, killing of the RPMI8866 target was inhibited in the 
presence of mAbs 1F7 and 1F8 at the 100:1 and 33:1 E:T ratios. 
mAb 1F7 blocked 14% of killing at the 100:1 ratio and 54% of killing 
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at the 33:1 ratio. mAh 1F8 blocked 13% of killing at the 100:1 ratio 
and 36% of killing at the 33:1 ratio. 
No significant effects on RPMI8866 target cell killing were 
noted when using the other antibodies also reactive with CD3", 
CD16+, CD56+ NK effector cells (mAbs 3D7, 1F9, 4B9, 3F6, 3E6, 4D10, 
3D5, 3E2) or in the presence of the isotype matched controls (shown 
in figures). Anti-LFA-1 antibody was used as a positve control which 
blocks killing by interfering with target cell adhesion. This screening 
procedure led to the identification of two hybridomas which secrete 
antibodies (mAbs 1F7 and 1F8) which inhibit the cytolytic activity of 




RPMI8866 + 1F7 mAb 
RPMI8866 + IgM mAb Control 
RPMI8866 + anti-LFA-1 mAb 
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RPMI8866 + anti-LFA-1 mAb 
Figure 11. Partial inhibition of NK cell cytotoxicity of RPMI8866 
stimulator cells by mAbs (A) 1F7 and (B) 1F8. 
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Demonstration of Allogeneic target recognition. In order to 
determine whether these mAbs were blocking NK killing in general, 
as opposed to allospecific killing, cytotoxicity assays were carried out 
with both RPMI8866 cells and K562 cells as targets in the presence 
of the mAbs and appropriate control mAbs. Although significant 
inhibition was achieved against killing of the RPMI8866 target as 
shown in Figure 11, the same antibodies at the same concentration 
did not significantly block killing of K562 at any of the effector : 
target ratios (Figure 12, A and B). This led to the identification of 
two hybridomas which secrete antibodies (mAbs 1F7 and 1F8) which 
inhibit the cytolytic activity of the NK cells against their original 
stimulator RPMI8866 but not of K562. That is, there appears to be a 
specificity to the antibody inhibitory effects. 
A 
1F7 




K562 + 1F7 mAb 
K562 + IgM mAb Control 
K562 + anfl-LFA-1 mAb —O—- 
K562 + 1F8 mAb 
K562 + IgGl mAb Control 
K562 + anti-LFA-1 mAb 
Figure 12. No effect on NK cytotoxicity of classical NK target K562 
by mAbs (A) 1F7 and (B) 1F8. 
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Are mAbs 1F7 and 1F8 recognizing CD56? Once functional 
significance was established for the surface molecules recognized by 
mAbs 1F7 and 1F8, more information regarding what they may be 
was desired. A flow cytometric experiment was completed in an 
attempt to rule out the possibility that mAbs 1F7 and 1F8 are 
recognizing isoforms of CD56, as anti-CD56 mAbs have failed to affect 
the lysis by NK cells of "nonspecific" targets, such as K562, while 
inhibiting the lysis of specific allogeneic target cells by a panel of 
alloreactive NK lines (2). 
In this experiment, mAbs 1F7 and 1F8, if not recognizing CD56, 
should have no effect on the staining of anti-CD56 PE or irrelevant 
PE. As a positive control, CD56 should block the staining of anti-CD56 
PE without blocking irrelevant PE. As seen in Figure 13, anti-CD56 
did not block the binding of anti-CD56 PE. Three possibilities explain 
this. First, the titer of the anti-CD56 was not known, and the amount 
used may have been too low to saturate cell surface molecules. 
Second, as previously discussed, there are multiple isoforms of CD56. 
These mAbs came from different hybridomas and may be 
recognizing different isoforms. Third, within isoforms, there are 
multiple non-crossblocking epitopes that these different mAbs could 
be recognizing. 
Monoclonal antibody 1F8 did not affect the binding of anti- 
CD56 PE. Monoclonal antibody 1F7, however, appears to have 
decreased the binding of anti-CD56 PE, lowering its mean 
fluorescence from >100 to <50. This may be due to nonspecific 
blocking of the anti-CD56 PE, and may be a result of the bulky 
pentameric structure of the 1F7 IgM antibody. Since CD56 is present 
only on NK cells and a minor subset of cytotoxic T cells, it is unlikely 
that mAb 1F8 recognizes CD56 on these cells as the molecule it 
recognizes are present at low densities on T cells (Figure 5). 
Furthermore, neither the RPMI8866 or K562 target cells express 
CD56, a requisite if CD56 mediated cytotoxicity is assumed to be the 
cause, according to the previously mentioned studies by Nitta et al. 
(32). This requirement, however, is disputed by Suzuki et al. (2). 
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Figure 13. Monoclonal antibody blocking experiment. NK cells 
were treated with mAbs 1F7, 1F8, or CD56, before treatment with, in 




NK lymphocytes have the ability to lyse target cells without 
apparent prior sensitization or MHC gene restriction (1-4). Despite 
the fact that NK cells have a limited target cell range, no specific NK- 
associated surface receptor or target ligand has yet been defined. 
Traditionally, it has been concluded that these cells, in contrast to T 
or B cells, lack a highly refined antigen recognition system, and are 
only nonspecific effectors. However, scrutiny of NK cytotoxic activity 
reveals heterogeneity of both NK recognition and target structrures 
(33). In addition, murine NK cells have been shown to mediate the 
genetically restricted hybrid resistance to parental bone marrow 
allografts (3), a phenomenon that appears directed at the products of 
noncodominant hematopoietic histocompatibility genes. More 
recently, evidence has been provided that human NK cells are 
capable of alloantigen recognition (19,20). Therefore, on the basis of 
these observations it would appear that, contrary to previous 
opinion, at least a subset of NK cells have the ability to distinguish 
target cells. 
The identification of surface structures involved in target cell 
recognition by NK cells has become an area of active investigation. 
Candidate markers must display a distribution restricted to 
functionally relevant effector cells, and antibodies directed against 
such putative receptors must alter the cytotoxic activity of such cells 
(3). In the present study, using NK cells stimulated with the NK- 
sensitive RPMI8866 B cell line as an immunogen, two mAbs (1F7 and 
1F8) were generated which inhibit lysis of RPMI8866 cells by CD3-, 
CD16+, CD56+ NK cells without affecting the ability of these cells to 
kill the classical NK target cell K562. 
Double fluorescence and FACS analysis showed that 1F7+ and 
1F8+ cells were consistently included in the CD3", CD16+, CD56+ cell 
populations. 1F7 mAb recognizes a surface molecule on these NK 
cells, and only questionably on B or T cells. The molecule recognized 
by mAb 1F8 is on NK and a percentage of T cells, while absent on B 
cells. It is not known if the 1F8+ T cells detected in activated 
cultures arise from expansion of a small number of positive cells 
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present in the peripheral blood, and/or if the molecule(s) is induced 
by activation of previously negative T cells. 
What do these mAbs recognize, and are they truly novel? 
Given that mAbs 1F7 and 1F8 inhibit target cell lysis, it is unlikely 
that they recognize CD2 or CD 16, since both anti-CD2 and anti-CD 16 
mAbs enhance NK-cell mediated killing (9,30). Studies using mAb 
against CD8, a surface structure shared by some NK cells and T cells, 
have failed to alter the cytotoxic activity of NK cells or the activity of 
these cells after activation by IL-2 (28). Unlike the molecules 
recognized by mAbs 1F7 and 1F8, CD2 is present on all T cells. 
Additionally, the patterns of antibody staining by anti-CD 16 and 
anti-CD8 differ from that of both anti-lF7 and anti-lF8 (Figures 9 
and 10). Monoclonal antibodies specific for CD45 have been reported 
to inhibit NK cell lysis of selected tumor cells, however, as it is 
expressed on virtually all hematopoietic cells except mature 
erythrocytes and their immediate precursors (30), it is unlikely to be 
recognized by mAbs 1F7 or 1F8. Monoclonal antibodies 1F7 and 1F8 
clearly do not recognize CD11/CD18 (LFA-1), because they do not 
block killing of K562 and, again, are subset-restricted. 
Immunofluorescence analysis of the NK cells could not refute 
the possibility that the antigenic epitopes recognized by these two 
mAbs are closely associated with, if not identical to CD56. Although 
mAb 1F8 does not block the staining pattern of anti-CD56 mAb, it is 
possible that it recognizes a non cross-blocking epitope. This may 
also be the case for mAb 1F7. It does affect the anti-CD56 mAb 
staining, but it is unclear that this effect is specific and not the result 
of non-specific blocking by a large IgM antibody. Using an irrelevent 
IgM antibody in this experiment would resolve this issue. The 
question of whether these mAbs recognize and block an epitope on 
NK CD56 is interesting because of the controversy regarding the 
function of CD56, and its significance with respect to the NK-target 
cell interaction. 
In the study by Nitta et ah, CD56 was reported to be involved 
in cytotoxic activity and only homotypic adhesion between NK cells 
and CD56+ malignant neural cells, because targets without CD56 were 
not susceptible to lysis by NK cells (31). In contrast, results obtained 

by Suzuki et al. suggests that CD56, of which they have detected at 
least four isoforms, is directly involved in NK cell lysis of alloantigen- 
specific targets (2). In their study, the lymphoblastoid cell line 
targets lacked any detectable expression of CD56, indicating that the 
CD56 isoforms on the NK cell effectors mediate a heterotypic rather 
than a homotypic interaction between NK cells and their targets. 
They used the finding of multiple CD56 isoforms on NK cells, the 
variable expression of these isoforms on allospecific NK lines, and the 
failure of any of their anti-CD56 mAbs to affect the lysis of NK cell of 
“nonspecific” targets such as K562 cells, to conclude that the CD56 
isoforms constitute an allorecognition apparatus. 
There is considerable information still to be obtained regarding 
these molecules. Plans for the future include: 1) Testing absolute 
specificity for the stimulator cells. Cold target inhibition studies 
could be done to confirm the specificity of the NK cells for the 
RPMI8866 stimulators. To prove that they truly block allospecific 
killing would require that they be tested with NK cells against a 
panel of target cells. 2) Phenotyping of additional cells for surface 
antigens recognized by mAbs 1F7 and 1F8. For example, staining 
freshly isolated T cells would answer the question of whether the 
1F8+ T cells detected in activated cultures arise from expansion of a 
small number of positive cells present in the peripheral blood, 
and/or if the molecule(s) is induced by activation of previously 
negative T cells. Generating NK clones and screening them for 
recognition by these mAbs would provide more information 
regarding heterogeneity of expression of the molecules they 
recognize. 3) Evaluating the possible role of molecules recognized by 
mAbs 1F7 and 1F8 in signal transduction. This can be accomplished 
by measuring Ca^+ fluxes resulting from mAb crosslinking. 
Assessing the ability of NK cells to specifically lyse the hybridoma 
cells that produce antibodies (mAbs 1F7 and 1F8) against a candidate 
triggering molecule on the effector cells, known as reverse ADCC, can 
also be used as a sensitive test for the ability of the molecule to 
transduce signals into the cell. For example, cytotoxic T cells 
specifically lyse anti-CD3 mAb-producing hybridomas, and human 
NK cells lyse anti-CD 16 mAb-producing hybridomas (27) and anti- 

CD56 mAb producing hybridomas (2). 4) Biochemistry. Immuno- 
precipitation and/or western blotting would be necessary to assess 
the molecular mass and extent of giycosylation of the surface 
antigens recognized by these mAbs. In order to conclude with 
certainty that mAbs 1F7 and 1F8 do or do not recognize CD56, their 
target ligand(s) would need to be immunoprecipitated and further 
characterized. And ultimately, 5) expression cloning from an 
RPMI8866-stimulated NK cell cDNA library, 6) sequencing, 7) 
transfection of cDNA into cells lacking NK activity, and 8) abrogation 
of expression of proposed cDNA in NK cells with antisense cDNA 
vectors. 
With this information in hand, it would be clarified whether 
the molecules recognized by mAbs 1F7 and 1F8 play a primary 
(receptor) or a secondary (accessory) role in antigen-specific killing. 
One would predict, if a molecule is a receptor involved in recognition 
and mediation of cell death by NK cells, that: 1) it would be present 
only on those cells that mediate this function; 2) absence of the 
molecule would be associated with lack of function; 3) the 
engagement of the molecule by its antibody would modulate its 
function; 4) affinity purified antibodies which block target killing 
could do so without disrupting primary target cell adhesion; 5) 
transfection of specific cytotoxic cells with the gene or cDNA of the 
molecule would enable them to mediate non-MHC-restricted killing; 
and 6) the ligand for the receptor would be expressed on appropriate 
target cells (27,28). 
At present it is only known that the molecules recognized by 
mAbs 1F7 and 1F8 fulfills two of these criteria. They are present 
only on those cells that lyse NK-sensitive targets and this killing is 
partially inhibited, when engaged by their respective antibodies. 
Taken together, these data suggest that 1F7 and 1F8 surface 
molecules may exert a role in the activation or regulation of the 
cytolytic function of human NK cells. The antigenic determinant 
recognized by 1F7 or 1F8 mAb could represent a "receptor" molecule 
uniquely expressed on NK cells. Determining whether either 
molecule is a true NK recognition receptor will require additional 
confirmation either by expression cloning, sequencing, and 
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transfection of a full-length cDNA into cells lacking NK activity or by 
abrogation of expression of the proposed receptor in NK cell lines or 
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